Neurizon

Governance

Updates

Announcements

Home

Space Grotesk

upload.jpg

Special Report: Neurizon Therapeutics has reported positive topline results from an open-label extension (OLE) study of its lead candidate NUZ-001 for amyotrophic lateral sclerosis (ALS), the major form of motor neurone disease.

Clinical-stage biotech developing treatments for neurodegenerative diseases Neurizon Therapeutics (ASX:NUZ) said the study reached its primary endpoint, showing long-term treatment with NUZ-001 at the phase II dose was safe and well tolerated.

Importantly, preliminary efficacy findings  demonstrated that treatment with NUZ compared to matched historical controls from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) showed:

Sustained slowing of global functional decline

Stockhead: Neurizon’s ALS drug shows safety and extended survival in open-label extension study